Brief Antecedent Ischemia Enhances Recombinant Tissue Plasminogen Activator–Induced Coronary Thrombolysis by Adenosine-Mediated Mechanism
Authors:
- 4 July 2000
- journal article
- other
- Published by Wolters Kluwer Health in Circulation
- Vol. 102 (1) , 88-95
Abstract
Background—Clinical studies have implicated preinfarct angina (brief antecedent ischemia/reperfusion [I/R]) as a predictor of more rapid thrombolysis and lower rates of reocclusion. However, the effects of antecedent ischemia on the efficacy of thrombolysis have not been rigorously assessed. Using a canine model of coronary thrombosis, we aimed to (1) reproduce these clinical findings and (2) determine whether release of adenosine (a potent inhibitor of platelet aggregation via stimulation of platelet A2receptors) during brief I/R contributes to this improved patency.Methods and Results—To address our first objective, we compared the time required to achieve lysis with recombinant tissue plasminogen activator and patency during the first 2 hours after lysis in dogs in which 1-hour thrombotic occlusion was preceded by brief I/R (10-minute coronary occlusion/10-minute reperfusion) versus 20-minute uninterrupted perfusion (controls). Time to lysis was accelerated in the I/R group versus the control group (11±1 versus 35±6 minutes,P=0.004). In addition, the duration of subsequent reocclusion was reduced (17±12 versus 30±11 minutes), and the area of the flow-time profile (normalized to baseline flow×120 minutes) was increased (64±12% versus 35±7%,P=0.04) in the I/R cohort. The protocol was then repeated, but all dogs were pretreated with the adenosine A2/A1antagonist CGS 15943 (CGS, 1.5 mg/kg). Time to lysis (38 versus 39 minutes) and subsequent patency were comparable in the CGS+control group versus the CGS+I/R group.Conclusions—Brief antecedent I/R enhances the efficacy of coronary thrombolysis in this canine model, which is due, at least in part, to an adenosine-mediated mechanism.Keywords
This publication has 20 references indexed in Scilit:
- Targeted Coronary Thrombolysis via “Pericardial” Administration of Lytic Agents?Journal of Thrombosis and Thrombolysis, 1998
- Endogenous adenosine inhibits P-selectin-dependent formation of coronary thromboemboli during hypoperfusion in dogs.Journal of Clinical Investigation, 1998
- Preinfarction Angina as a Predictor of More Rapid Coronary Thrombolysis in Patients with Acute Myocardial InfarctionNew England Journal of Medicine, 1996
- Adenosine and Coronary Vascular Pharmacology1996
- Stuttering reperfusion of ischemic myocardium does not exacerbate myocardial infarction: Evidence against lethal cell reperfusion injury in the rabbitJournal of Thrombosis and Thrombolysis, 1996
- Effects of the new A2 adenosine receptor antagonist 8FB‐PTP, an 8 substituted pyrazolo‐triazolo‐pyrimidine, on in vitro functional modelsBritish Journal of Pharmacology, 1994
- Hemodynamic, mechanical, and metabolic determinants of thrombolytic efficacy: A theoretic framework for assessing the limitations of thrombolysis in patients with cardiogenic shockAmerican Heart Journal, 1993
- The adenosine/neutrophil paradox resolved: human neutrophils possess both A1 and A2 receptors that promote chemotaxis and inhibit O2 generation, respectively.Journal of Clinical Investigation, 1990
- Relationship between antecedent angina pectoris and short-term prognosis after thrombolytic therapy for acute myocardial infarctionAmerican Heart Journal, 1990
- Balloon angioplasty. Natural history of the pathophysiological response to injury in a pig model.Circulation Research, 1985